CORMEDIX INC. - COMMON STOCK

CorMedix Inc. Announces Appointment of Chief Legal Officer

15 Dec 2023 07:30:00 By Nasdaq GlobeNewswire

CorMedix Inc. Announces Partnership With The Leapfrog Group

04 Dec 2023 07:30:00 By Nasdaq GlobeNewswire

CorMedix Inc. Announces FDA Approval of DefenCath® to Reduce the Incidence of Catheter-Related Bloodstream Infections in Adult Hemodialysis Patients

15 Nov 2023 11:57:47 By Nasdaq GlobeNewswire

CorMedix Inc. Reports Third Quarter and Nine Month 2023 Financial Results and Provides Business Update

14 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

CorMedix Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on November 14, 2023

02 Nov 2023 07:30:00 By Nasdaq GlobeNewswire

CorMedix Inc. Announces Abstract Presentation at Upcoming IDWeek Conference

11 Oct 2023 07:30:00 By Nasdaq GlobeNewswire

CorMedix Inc. to Present at the Cantor Fitzgerald Global Healthcare Conference

26 Sep 2023 07:30:00 By Nasdaq GlobeNewswire

CorMedix Inc. Announces Publication of Phase 3 LOCK IT-100 Study Data in the Clinical Journal of The American Society of Nephrology

08 Sep 2023 07:30:00 By Nasdaq GlobeNewswire

CorMedix Inc. to Present at the H.C. Wainwright Annual Global Investment Conference

06 Sep 2023 07:30:00 By Nasdaq GlobeNewswire

CorMedix Inc. Announces Issuance of U.S. Patent Covering Lead Product Defencath

30 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

CorMedix Inc. Reports Second Quarter and Six Month 2023 Financial Results and Provides Business Update

08 Aug 2023 06:30:00 By Nasdaq GlobeNewswire

CorMedix Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on August 8, 2023

26 Jul 2023 07:30:00 By Nasdaq GlobeNewswire

CorMedix Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Pre-Funded Warrants

28 Jun 2023 21:57:02 By Nasdaq GlobeNewswire

CorMedix Inc. Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

28 Jun 2023 15:07:53 By Nasdaq GlobeNewswire

CorMedix Inc. Announces FDA Acceptance of Resubmission of New Drug Application for DefenCath

21 Jun 2023 07:30:00 By Nasdaq GlobeNewswire

Cormedix Inc. Announces Strategic Initiative With Boston Medical Center to Reduce Health Disparities in Patients at Risk for Bloodstream Infections

15 Jun 2023 07:30:00 By Nasdaq GlobeNewswire

Cormedix Inc. To Present At The Jefferies Healthcare Conference

30 May 2023 07:30:00 By Nasdaq GlobeNewswire

CorMedix Inc. Announces Resubmission of New Drug Application for DefenCath

16 May 2023 06:00:01 By Nasdaq GlobeNewswire

CorMedix Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

15 May 2023 15:05:01 By Nasdaq GlobeNewswire

CorMedix Inc. To Report First Quarter 2023 Financial Results and Provide a Corporate Update on May 15, 2023

08 May 2023 07:30:00 By Nasdaq GlobeNewswire